Akero Therapeutics (AKRO) Stock Highlights

41.95 | +8.57%

2025-04-03 03:00:07

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The companys product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.

Statistics

Range Today

38.07 41.96

Volume Today 1.69M

Range 1 Year

17.86 58.4

Volume 1 Year 207.28M

Range 3 Year

7.52 58.4

Volume 3 Year 704.76M

Range 10 Year

7.52 58.4

Volume 10 Year 854.09M

Highlights

Market Capitalization 3.4B (mid)

Floating Shares 66.4M

Current Price 41.95

Price To Earnings -11.93

Price To Book 4.12

Earnings Per Share -3.75

Payout Ratio 0%

Performance

Latest +8.57%

1 Month -12.77%

3 Months +49.39%

6 Months +46.78%

1 Year +78.89%

3 Years +182.49%

5 Years +119.75%

10 Years +159.59%

Benchmarks

Market Capitalization

0 / 368

Gross Profits

0 / 278

Total Revenue

0 / 300

Total Rank

0 / 368

Free Cashflow

0 / 352

Performance 5 years

0 / 368

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.